申联生物
(688098)
| 流通市值：34.29亿 | | | 总市值：34.29亿 |
| 流通股本：4.11亿 | | | 总股本：4.11亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 111,920,730.05 | 62,598,409.64 | 288,266,467.14 | 237,694,760.86 |
| 营业收入 | 111,920,730.05 | 62,598,409.64 | 288,266,467.14 | 237,694,760.86 |
| 二、营业总成本 | 126,866,313.85 | 60,149,695.32 | 306,578,474.55 | 235,297,261.25 |
| 营业成本 | 47,721,950.03 | 23,004,432.61 | 124,472,327.95 | 96,280,433.54 |
| 税金及附加 | 2,684,835.52 | 1,388,425.29 | 3,033,914.33 | 3,454,642.14 |
| 销售费用 | 36,943,047.69 | 15,588,754.47 | 80,794,970.67 | 62,518,067.78 |
| 管理费用 | 21,948,324.02 | 11,578,848.73 | 53,496,180.34 | 41,836,977.97 |
| 研发费用 | 17,516,450.5 | 8,565,273.75 | 44,814,670.03 | 31,220,699.23 |
| 财务费用 | 51,706.09 | 23,960.47 | -33,588.77 | -13,559.41 |
| 其中:利息费用 | 246,758.44 | 62,790 | 532,059.55 | 203,354.66 |
| 其中:利息收入 | 224,078.44 | 53,268.94 | 625,109.75 | 262,231.57 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -351,384.03 | -293,598.83 | 2,402,823.06 | 1,697,916.05 |
| 加:投资收益 | -1,052,162.51 | -180,149.58 | -3,004,545.84 | -1,165,933.07 |
| 资产处置收益 | -197,942.15 | -419.27 | 260,766.69 | 269,871.6 |
| 资产减值损失(新) | -11,582.17 | -44,044.33 | 6,259.52 | 11,580.1 |
| 信用减值损失(新) | -8,707,588.4 | -5,392,669.64 | -13,322,888.83 | -9,595,240.4 |
| 其他收益 | 1,358,110.28 | 641,497.39 | 4,111,742.18 | 3,773,232.91 |
| 四、营业利润 | -23,908,132.78 | -2,820,669.94 | -27,857,850.63 | -2,611,073.2 |
| 加:营业外收入 | 93.5 | 93.5 | 1,593,803.5 | 1,265,674.6 |
| 减:营业外支出 | 6,356.29 | 6,323.9 | 46,445.86 | 3,221.41 |
| 五、利润总额 | -23,914,395.57 | -2,826,900.34 | -26,310,492.99 | -1,348,620.01 |
| 减:所得税费用 | -3,556,609.99 | -464,432.09 | -1,338,901.59 | 1,674,251.99 |
| 六、净利润 | -20,357,785.58 | -2,362,468.25 | -24,971,591.4 | -3,022,872 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -20,357,785.58 | -2,362,468.25 | -24,971,591.4 | -3,022,872 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -19,146,404.15 | -1,730,954.9 | -20,495,002.98 | 278,051.56 |
| 少数股东损益 | -1,211,381.43 | -631,513.35 | -4,476,588.42 | -3,300,923.56 |
| 扣除非经常损益后的净利润 | -19,155,805.56 | -1,829,885.14 | -25,984,564.06 | -5,100,650.29 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.05 | 0 | -0.05 | 0 |
| (二)稀释每股收益 | -0.05 | 0 | -0.05 | 0 |
| 九、综合收益总额 | -20,357,785.58 | -2,362,468.25 | -24,971,591.4 | -3,022,872 |
| 归属于母公司股东的综合收益总额 | -19,146,404.15 | -1,730,954.9 | -20,495,002.98 | 278,051.56 |
| 归属于少数股东的综合收益总额 | -1,211,381.43 | -631,513.35 | -4,476,588.42 | -3,300,923.56 |
| 公告日期 | 2026-08-31 | 2026-04-29 | 2026-04-29 | 2025-10-27 |
| 审计意见(境内) | | | 标准无保留意见 | |